Valuation: Tengion, Inc.

Market Cap 1L 97.69T 90.54T 82.04T 2L 1.04Cr 2L 10.86L 4L 54.41L 4L 4L 1.74Cr P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 55.52L 49.42L 45.8L 41.5L 78L 53Cr 79.3L 5.5Cr 2.16Cr 28Cr 2.08Cr 2.04Cr 88Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.02
10 years 0
Extreme 1.0E-6
0.04
Change 5-day change 1-year change 3-year change Capi.($)
+900.00%-.--% - - 402
+0.79%-6.46%+52.86%+71.34% 6.58TCr
+1.92%+8.89%+12.90%+82.75% 5.19TCr
+6.91%+6.41%+9.61%+73.07% 5.12TCr
+0.74%+2.75%+26.31%+45.29% 4.38TCr
+3.87%+10.15%+20.69%+132.73% 4.21TCr
+7.91%+4.30%+263.91%+602.72% 3.9TCr
-0.40%+9.42%+18.44%+59.06% 3.4TCr
+3.84%-4.94%+42.35%+8.92% 2.52TCr
+2.36%+4.62%+24.20%+31.02% 2.28TCr
Average +92.90%+0.46%+52.36%+122.99% 3.76TCr
Weighted average by Cap. +3.17%+0.62%+51.12%+124.45%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.51Cr -1.4Cr -1.27Cr -2.38Cr -160.37Cr -2.42Cr -17Cr -6.58Cr -84Cr -6.35Cr -6.22Cr -267.74Cr -1.89Cr -1.68Cr -1.56Cr -1.41Cr -2.66Cr -179.3Cr -2.7Cr -19Cr -7.36Cr -94Cr -7.1Cr -6.95Cr -299.33Cr
Net Debt 37.33L 33.23L 30.8L 27.91L 52.44L 35Cr 53.32L 3.7Cr 1.45Cr 19Cr 1.4Cr 1.37Cr 59Cr 54.42L 48.44L 44.89L 40.68L 76.45L 52Cr 77.73L 5.39Cr 2.12Cr 27Cr 2.04Cr 2Cr 86Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
26
  1. Stock Market
  2. Stocks
  3. TNGNQ Stock